Reversal of cisplatin resistance in vivo by an anti-fos ribozyme

In Vivo

Volumn 11, Issue 3, 1997, Pages 217-220

  Funato, Tadao ^a   Ishii, Tomonori ^a   Kanbe, Mariko ^a   Scanlon, Kevin J ^b   Sasaki, Takeshi ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b BAYER AG   (Germany)

Author keywords

C fos; Cisplatin; Colon cancer; Drug resistance; Ribozyme

Indexed keywords

CISPLATIN; MESSENGER RNA; RIBOZYME;

ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; DNA TRANSFECTION; DRUG RESISTANCE; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; ONCOGENE C FOS; TUMOR SUPPRESSOR GENE;

EID: 0030834378     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Angel P,Imagawa M, Chiu R, Stein B, Imbra RJ, Rahmdof HJ, Jonat C, Herrlich P, and Karin M: Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 49: 729-739, 1987.
2. Abate C, Luk D, Gentz R, Rausher IIIVFJ and Curran T: Expresion and purification of the leucine zipper and DNA-binding domains of Fos and Jun: both Fos and Jun contact DNA directly. Proc Natl Acad Sci USA 87; 1032-1036, 1990.
3. Scanlon KJ, Kashani-Sabet M, Miyachi H, Sowers L and Rossi JJ: Molecular basis of cisplatin resistant human carcinomas: Model systems and patients. Anticancer Res 9: 1301-1312, 1989.
4. Curran T and Franza BR: Fos and Jun: The AP-1 connection. Cell 55: 395-397, 1988.
5. Scanlon KJ, Kashani-Sabet M, Tone T and Funato T: Cisplatin resistance in human cancers. Pharmac Ther 52: 385-406, 1991.
6. Scanlon KJ, Ohta Y, Ishida H, Kijima H, Ohkawa T, Kaminski A, Tsai J, Horng G and Kashani-Sabet M: Oligonucleotide-mediated modulation of mammalian gene expression. FASEB J 9: 1288-1296, 1995.
7. Cech TR and Bass BL: Biological catalysis by RNA. Annu Rev Biochem 55: 599-629, 1986.
8. Kashani-Sabet M and Scanlon KJ: Application of ribozymes to cancer gene therapy. Cancer Gene Ther 2: 213-223, 1995.
9. Scanlon KJ, Jiao L, Funato T, Wang W, Tone T, Rossi JJ and Kashani-Sabet M: Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA 88: 10591-10595, 1991.
10. Funato T, Yoshida E, Jiao L, Tone T, Kashani-Sabet M and Scanlon KJ: The utility of an antifos ribozyme in reversing cisplatin resistance in human carcinomas. Advan. Enzyme Regul 32: 195-209, 1992.
11. Kashani-Sabet M, Funato T, Tone T, Jiao L, Wang W, Yoshida E, Kashfian BI, Shitara T, Wu A, Moreno JG, Traweek ST, Ahlering TE and Scanlon KJ: Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res.Dev. 2:3-15, 1992.
12. Fodstad O: Transplantability of human tumors. In: E. Boven and B. Winograd (eds.), Nude mice in Oncology Research, pp.66-76, Boca Raton, FL: CRC Press, 1991.
13. Yu M, Ojwang J, Yamada O, Hempel A, Rappoport J, Looney D, and Wong-Staal F: A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type I. Proc Natl Acad Sci USA 90: 6340-6344, 1993.
14. Heidenreich O, Benseler F, Fahrenholz A and Eckstein F: High activity and stability of hammerhead ribozymes containing 2′-modified pyrimidine nucleosides and phosphorothioates. J Biol Chem 269: 2131-2138, 1994.
15. Feng M, Cabrera G, Deshane J, Scanlon KJ and Curiel DT: Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of anti-ras ribozyme. Cancer Res. 55: 2024-2028, 1995.
16. Miller D: Targeted vectors for gene therapy. FASEB J 9: 190-199, 1995.